Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.


TSX:QIPT - Post by User

Post by besttobeon Jun 15, 2023 5:38pm
153 Views
Post# 35498999

HME article-VENTILATOR ACCESS, BID RELIEF SUPPORT

HME article-VENTILATOR ACCESS, BID RELIEF SUPPORT

REGULATORY UPDATE: VENTILATOR ACCESS, BID RELIEF SUPPORT 

ARLINGTON, Va. – AAHomecare and the ALS Association asked CMS to promptly issue a memorandum clarifying medical policy and coverage of non-invasive ventilators (NIVs) and take steps to expedite authorizations for people living with ALS. 

They shared their concerns about reports of denials as high as 86% and 64% for two major MA plans, with rates in the low teens for other MA plans. They report issues for both new setups and continued authorizations. 

“The ALS Association representatives and clinicians provided first-hand accounts of the devastating impacts that delays and denials can have on patients and their caregivers,” the association stated. “The advocates drove home the notion that physicians who have examined and made a clinical assessment of a patient are best positioned to determine the type of respirator needed – not MA plan prior authorization and utilization staff.”   

AAHomecare representatives Tom Ryan, David Chandler and Cara Bachenheimer were joined by ALS Association representatives Kathleen Sheehan and Cynthia Knoche. Dr. Lisa Wolf and Dr. John Hansen-Flaschen, prominent physicians who treat ALS patients, also took part in the meeting. CMS was represented by its Deputy Director, Parts C and D, as well as the Director and Deputy Director of Drug and Health Plan Contact Administration.  
 
Bid relief support 

Twenty-five national, regional and state HME associations have joined AAHomecare in writing a letter in support of S. 1294, which would extend the 75/25 blended Medicare reimbursement rate for suppliers in non-rural, non-competitive bidding areas through the end of 2024. 

In their letter to the bill’s original sponsors, Sens. John Thune, R-S.D., and Debbie Stabenow, D-Mich., the associations note that rising product and operational costs “are being shouldered by DME suppliers who continue receiving price increase notifications from their vendor partners, as well as increased delivery and operational costs, while facing fixed reimbursement rates.” 

AAHomecare recommends that stakeholders use the letter when contacting senators to support the bill. 

“We need to continue to press legislators to co-sponsor S.1294 in June and July and begin to build momentum for consideration later this year,” the association states. “Convincing Senators to co-sponsor legislation can be a challenging process but building a base of bipartisan support for the S. 1294 is critical for the bill’s consideration. Support from members of the Senate Finance Committee is especially important.” 


<< Previous
Bullboard Posts
Next >>